Analysts' Actions: CMA CRI DOV F GM

NEW YORK (TheStreet) -- RATINGS CHANGES

Apollo Global Management (APOL) was upgraded to hold at TheStreet Ratings.

Comerica (CMA) was upgraded at Wells Fargo to market perform from underperform. Company is leveraged to better commercial lending activity, Wells Fargo said.

CenterPoint Energy (CNP) was upgraded to buy at TheStreet Ratings.

Carter's (CRI) was upgraded at Piper Jaffray to overweight from neutral. Twelve-month price target is $92. Company can deliver solid execution in the presence of a favorable secular backdrop, Piper Jaffray said.

Cognizant Technology Solutions (CTSH) was upgraded at UBS to buy from neutral. Well-positioned for the current demand environment, and more formal capital return policy could be announced later this year, UBS said. Twelve-month price target is $58.

Dover (DOV) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $93. Estimates were also boosted, as acquisitions can help augment consistent double-digit earnings growth, Credit Suisse said.

DSW (DSW) was upgraded at Brean Capital to hold from sell. Valuation call, as the stock is already pricing in a lot of bad news, Brean Capital said.

Edison (EIX) was downgraded at Argus to hold from buy. Valuation call, as the stock is up 27% since mid-January, Argus said.

Ford (F) was initiated with a neutral at Nomura. Twelve-month price target is $15. North America margins may have peaked, Nomura said.

Fortinet (FTNT) was upgraded at Wells Fargo to outperform from market perform. Improved refresh cycle and better network security spending could drive higher growth, Wells Fargo said.

General Motors (GM) was initiated with a "reduce" rating at Nomura. Twelve-month price target is $32. China margins appear to be peaking, Nomura said.

Intuitive Surgical (ISRG) was upgraded at JMP Securities to outperform from underperform. Twelve-month price target is $700. Estimates were also boosted, following the FDA approval of the fourth-generation da Vinci system, JMP Securities said.

National Fuel Gas (NFG) was initiated at Jefferies with a buy rating. Company offers a secure and growing dividend, significant leverage to LT Appalachian E&P and midstream opportunities, and potential for MLP formation, Jefferies said. Twelve-month price target is $79.

Penske (PAG) was upgraded at Sterne Agee to buy from neutral. Twelve-month price target is $52. Estimates were also increased, as the company has a lot of earnings momentum, Sterne Agee said.

Questar (STR) was initiated at Jefferies with a hold rating. Company offers exposure to the entire natural gas value chain, and stock offers a defensive equity play with high returns and attractive dividend growth, Jefferies said. Twelve-month price target is $24.

Southwest Gas (SWX) was initiated at Jefferies with a hold rating. Poised to benefit from ongoing regional economic and housing recoveries, Jefferies said. Twelve-month price target is $55.

Veeva (VEEV) was upgraded at Morgan Stanley to overweight. Twelve-month price target is $40. Market is underestimating the company's potential outside SFA, Morgan Stanley said.

Worthington (WOR) was upgraded at Keybanc to buy from hold. Twelve-month price target is $46. Stock has pulled back, but the long-term growth thesis remains intact, Keybanc said.

Stock Comments / EPS Changes

Crown Holding (CCK) 12-month price target was raised at Jefferies to $53. Driven by upside to company synergy targets, Jefferies said.

Green Plains (GPRE) 12-month price target, EPS estimates were raised at Jefferies. Driven by combination of strong ethanol margins and optimism of a favorable settlement of RFS debate, Jefferies said. Twelve-month price target is now $40. Buy rating.

Marvell Technology (MRVL) 12-month price target was increased at UBS to $17. Driven by increasing revenue momentum and second half from 3G and 4G TD-LTE SoCs, UBS said.

Maxim Integrated Products (MXIM) 12-month price target was increased at Jefferies to $39. Company is poised to see an order snapback from Samsung, and Samsung inventory has played out, Jefferies said.

Myriad Genetics (MYGN) 12-month price target was increased at Jefferies to $33. Driven by unexpected boost to BRCA pricing, Jefferies said.

Sally Beauty (SBH) numbers were cut at Sterne Agee. Twelve-month price target is now $32. Estimates were also reduced, given weather impacts, Sterne Agee said. Buy rating.

Follow TheStreet on Twitter and become a fan on Facebook

More from Stocks

Tesla's Elon Musk Just Told Short-Sellers They're Toast

Tesla's Elon Musk Just Told Short-Sellers They're Toast

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dropbox Soars in Third-Straight Record-Setting Session

Dropbox Soars in Third-Straight Record-Setting Session

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Jim Cramer on the Markets: I Struggle With How Negative Things Are